Welcome to our dedicated page for Concord Medical SEC filings (Ticker: CCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Concord Medical Services Holdings Limited filings document the formal disclosures of a foreign private issuer operating oncology healthcare services in China. Annual reports and current reports cover audited financial statements, hospital and network business results, cancer-care operations, radiotherapy and diagnostic imaging services, proton therapy assets, and governance disclosures.
Form 6-K filings record shareholder meeting materials, proxy forms, director changes, interim and annual disclosures from Concord Healthcare Group, and capital actions at the Hong Kong-listed subsidiary. The filing record also documents public-company reporting around Form 20-F status, ordinary-share governance, subsidiary H-share activity, and material press releases furnished to the SEC.
Concord Medical Services Holdings Limited (NYSE: CCM) filed a Form 6-K to disclose that its Hong Kong–listed subsidiary, Concord Healthcare Group Co., Ltd. (HKSE: 2453.HK), experienced a reduction in the stake held by one of its controlling shareholders. On 20 June 2025, Beijing Concord Medical Technology Co., Ltd. sold 32,800,000 H shares of Concord Healthcare via block trade at HK$6.12 per share, equal to approximately 4.46 % of Concord Healthcare’s issued share capital. The filing reiterates that Concord Healthcare’s H shares were listed on the HKSE on 9 January 2024 and directs investors to the HKSE website for transaction details.
No additional financial results, earnings data or strategic initiatives were reported in this 6-K.